Literature DB >> 18158738

Multiple antigenic peptides as vaccine platform for the induction of humoral responses against dengue-2 virus.

Georgios Amexis1, Neal S Young.   

Abstract

Dengue is an important agent of human disease for which no licensed vaccine is available to the public. We used multiple antigenic peptides (MAPs) as an antigen carrier for the development of subunit vaccines against dengue-2 virus (DEN-2). Commercially available software (MacVector 7.0) was used to identify potential antigenic B-cell epitopes of E-glycoprotein. A total of 60 BALB/c mice were immunized with 12 recombinant DEN-2-specific MAPs and the humoral immune response was assessed by anti-DEN-2 ELISA and PRNT50 assays. Anti-DEN-2 ELISA showed high levels of anti-DEN-2 antibodies and post-immune sera reduced viral infectivity and prevented infection of monkey kidney cells (LLC-MK2) with live DEN-2 virus. Seven neutralizing DEN-2 epitopes were identified that generated PRNT50 titers of up to 1:160. Our findings show that the MAP platform can be used as an antigen-presenting platform for dengue vaccine development.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18158738     DOI： 10.1089/vim.2007.0029

Source DB:  PubMed          Journal:  Viral Immunol        ISSN： 0882-8245            Impact factor:   2.257


  8 in total

1.  Enhancement of SIV-specific cell mediated immune responses by co-administration of soluble PD-1 and Tim-3 as molecular adjuvants in mice.

Authors:  Lijun Xiao; Dimin Wang; Caijun Sun; Pingchao Li; Yi Jin; Liqiang Feng; Ling Chen
Journal:  Hum Vaccin Immunother       Date:  2013-12-10       Impact factor: 3.452

2.  Overexpression of heparanase multiple antigenic peptide 2 is associated with poor prognosis in gastric cancer: Potential for therapy.

Authors:  Jun Zhang; Jianmin Yang; Xiaomei Han; Zhongsheng Zhao; Ling DU; Tong Yu; Huiju Wang
Journal:  Oncol Lett       Date:  2012-05-04       Impact factor: 2.967

3.  The nature and combination of subunits used in epitope-based Schistosoma japonicum vaccine formulations affect their efficacy.

Authors:  Xuefeng Wang; Lei Zhang; Ying Chi; Jason Hoellwarth; Sha Zhou; Xiaoyun Wen; Lei He; Feng Liu; Calvin Wu; Chuan Su
Journal:  Parasit Vectors       Date:  2010-11-19       Impact factor: 3.876

4.  A Multiple Antigenic Peptide Mimicking Peptidoglycan Induced T Cell Responses to Protect Mice from Systemic Infection with Staphylococcus aureus.

Authors:  Xiang-Yu Wang; Zhao-Xia Huang; Yi-Guo Chen; Xiao Lu; Ping Zhu; Kun Wen; Ning Fu; Bei-Yi Liu
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

5.  Evaluation of protective efficacy using a nonstructural protein NS1 in DNA vaccine-loaded microspheres against dengue 2 virus.

Authors:  Shih-shiung Huang; I-Hsun Li; Po-da Hong; Ming-kung Yeh
Journal:  Int J Nanomedicine       Date:  2013-08-19

6.  Synthetic B-Cell Epitopes Eliciting Cross-Neutralizing Antibodies: Strategies for Future Dengue Vaccine.

Authors:  Babu Ramanathan; Chit Laa Poh; Kristin Kirk; William John Hannan McBride; John Aaskov; Lara Grollo
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

Review 7.  Anaplasma marginale: Diversity, Virulence, and Vaccine Landscape through a Genomics Approach.

Authors:  Rosa Estela Quiroz-Castañeda; Itzel Amaro-Estrada; Sergio Darío Rodríguez-Camarillo
Journal:  Biomed Res Int       Date:  2016-08-17       Impact factor: 3.411

8.  Expansion and Refinement of Deep Sequence-Coupled Biopanning Technology for Epitope-Specific Antibody Responses in Human Serum.

Authors:  Nikole L Warner; Alexandria C Linville; Susan B Core; Brechla Moreno; Juan M Pascale; David S Peabody; Bryce Chackerian; Kathryn M Frietze
Journal:  Viruses       Date:  2020-09-30       Impact factor: 5.048
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.